Gilead Sciences has announced findings from two phase III trials that demonstrate the benefits of its drug Vemlidy in the treatment of chronic hepatitis B.
At the International Liver Congress in Amsterdam, 96-week results from two ongoing studies were presented, highlighting the safety and efficacy of daily Vemlidy treatment in immune active patients and those switching from Gilead's established therapy Viread.
“Gilead Sciences has reported new clinical trial data demonstrating the effectiveness of Vemlidy as a treatment for chronic hepatitis B.“
The drug was shown to offer antiviral efficacy that is noninferior to Viread in patients with chronic hepatitis B viral (HBV) infections, as well as a beneficial impact on renal and bone laboratory safety parameters compared to Viread.
High rates of viral suppression were also observed, with no evidence of resistance, and less impact on renal and bone safety parameters than Viread.
Dr Norbert Bischofberger, executive vice-president of research and development and chief scientific officer at Gilead, said: "The results observed in these studies reinforce Vemlidy as an important treatment option for patients living with chronic HBV infection."
Vemlidy is a novel, targeted prodrug of tenofovir that was approved by the European Commission earlier this year.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical